Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 85% of all cases. In recent years, its treatment has changed dramatically with the advent of molecularly targeted therapies such as EGFR inhibitors and immune checkpoint inhibitors such as anti-PD-1 antibodies. They have been shown to be effective not only in unresectable advanced or recurrent cases but also as adjuvant or preoperative therapies, and their indications are expanding. On the other hand, the increasing number of treatment options has left clinicians scratching their heads as to what the optimal therapy is. In particular, the treatment of stage III-N2 NSCLC is controversial.
Currently, preoperative immunotherapy is an option for stage III-N2 NSCLC, but the results of the PACIFIC trial are also important and should be compared. Surgery after preoperative chemoradiotherapy and postoperative adjuvant therapy with osimertinib or atezolizumab are also options, if only in EGFR-positive cases. Thus, there are multiple treatment options for stage III-N2 NSCLC, and the therapies implemented are expected to vary from institution to institution. Our goal is to collect real-world data, results of prospective trials, and meta-analyses on the treatment of stage III-N2 NSCLC to discuss the role of immune checkpoint inhibitors and molecular targeted therapy in the treatment of stage III-N2 NSCLC.
This research topic aims to provide an overview of the latest advances in the use of immune checkpoint inhibitors and molecularly targeted therapies in the treatment of stage III-N2 NSCLC, with the ultimate goal of improving patient outcomes. Original articles, review articles, systematic reviews, case reports, and perspectives by experts in the field are welcome.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 85% of all cases. In recent years, its treatment has changed dramatically with the advent of molecularly targeted therapies such as EGFR inhibitors and immune checkpoint inhibitors such as anti-PD-1 antibodies. They have been shown to be effective not only in unresectable advanced or recurrent cases but also as adjuvant or preoperative therapies, and their indications are expanding. On the other hand, the increasing number of treatment options has left clinicians scratching their heads as to what the optimal therapy is. In particular, the treatment of stage III-N2 NSCLC is controversial.
Currently, preoperative immunotherapy is an option for stage III-N2 NSCLC, but the results of the PACIFIC trial are also important and should be compared. Surgery after preoperative chemoradiotherapy and postoperative adjuvant therapy with osimertinib or atezolizumab are also options, if only in EGFR-positive cases. Thus, there are multiple treatment options for stage III-N2 NSCLC, and the therapies implemented are expected to vary from institution to institution. Our goal is to collect real-world data, results of prospective trials, and meta-analyses on the treatment of stage III-N2 NSCLC to discuss the role of immune checkpoint inhibitors and molecular targeted therapy in the treatment of stage III-N2 NSCLC.
This research topic aims to provide an overview of the latest advances in the use of immune checkpoint inhibitors and molecularly targeted therapies in the treatment of stage III-N2 NSCLC, with the ultimate goal of improving patient outcomes. Original articles, review articles, systematic reviews, case reports, and perspectives by experts in the field are welcome.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
